NCT05630066 (Aldebaran) is a Phase 2 clinical trial of Alogabat in Angelman Syndrome, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT05630066?

NCT05630066 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT05630066?

Interventions in NCT05630066: Alogabat.

What condition does NCT05630066 study?

NCT05630066 studies Angelman Syndrome.

Is NCT05630066 still recruiting?

NCT05630066 is currently completed. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT05630066: Aldebaran

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

Completed Phase 2 Last updated 4 December 2025

What this trial tests

Phase 2 trial testing Alogabat in Angelman Syndrome in 48 participants. Completed in 2 December 2025.

Timeline

27 July 2023

Primary endpoint
2 December 2025

2 December 2025

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	27 July 2023
Primary completion	2 December 2025
Estimated completion	2 December 2025
Sites	19 locations across France, Italy, Germany, Australia, United States, Spain

Drugs / interventions tested

Alogabat — full drug profile →

Conditions studied

Angelman Syndrome — all drugs for Angelman Syndrome →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Adults 5 to 17, any sex, with Angelman Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Preclinical pharmacology of alogabat: a novel GABA<sub>A</sub>-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABA<sub>A</sub> signaling.
Cecere G, Ballard TM, Knoflach F, Honer M, et al · · 2025 · cited 3× · PMID 40761395 · DOI 10.3389/fphar.2025.1626078
Using the Bayley-4 and Vineland-3 in Angelman syndrome: barriers, solutions, and challenging items.
Halpin SN, Potter SN, Gwaltney A, Sadhwani A, et al · · 2025 · cited 1× · PMID 40462183 · DOI 10.1186/s13023-025-03817-x
Crossing the finish line towards a disease-modifying treatment for Angelman syndrome.
Judson MC, de Almeida LP, Burdine RD, Chamberlain SJ, et al · · 2026 · PMID 41795090 · DOI 10.1186/s11689-026-09681-5

Verify or expand the search:

Other recruiting trials for Angelman Syndrome

Currently open trials in the same condition.

NCT07181837 — A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome · Phase 1, PHASE2 · recruiting
NCT06353620 — Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy · recruiting
NCT06115109 — Angelman Natural History Study - FAST Spain · recruiting
NCT05293184 — The Global Angelman Syndrome Registry · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05630066 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05630066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing